You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentamidine
Accession NumberDB00738  (APRD00303, EXPT02625)
TypeSmall Molecule
GroupsApproved
DescriptionAntiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [PubChem]
Structure
Thumb
Synonyms
1,5-Bis(4-amidinophenoxy)pentane
4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide
4,4'-(Pentamethylenedioxy)dibenzamidine
4,4'-Diamidinodiphenoxypentane
P,P'-(pentamethylenedioxy)dibenzamidine
Pentamidin
Pentamidina
Pentamidindiisetionat
Pentamidine
Pentamidinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nebupentinhalant300 mg/6mLrespiratory (inhalation)APP Pharmaceuticals, LLC2011-02-15Not applicableUs
Pentacarinat 300 Inj Pws 300mg/vialpowder for solution300 mgintramuscular; inhalation; intravenousAventis Pharma Inc1989-12-312005-08-01Canada
Pentam 300injection, powder, lyophilized, for solution300 mg/3mLintramuscular; intravenousAPP Pharmaceuticals, LLC2001-01-16Not applicableUs
Pentamidine Isethionate Inj 300mg/vial BPpowder for solution300 mgintramuscular; intravenousDavid Bull Laboratories (Pty) Ltd.1990-12-311998-08-13Canada
Pentamidine Isetionate for Injection, BPpowder for solution300 mgintramuscular; intravenousHospira Healthcare Corporation1998-09-10Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PentacarinatSanofi-Aventis
PentacrinatAbbot
PentamAbbot
Pentamidine isethionateAbbot
PneumopentNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pentamidine Isethionate
ThumbNot applicableDBSALT000967
Categories
UNII673LC5J4LQ
CAS number100-33-4
WeightAverage: 340.4195
Monoisotopic: 340.189926032
Chemical FormulaC19H24N4O2
InChI KeyInChIKey=XDRYMKDFEDOLFX-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
IUPAC Name
4-{[5-(4-carbamimidoylphenoxy)pentyl]oxy}benzene-1-carboximidamide
SMILES
NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Alkyl aryl ether
  • Carboximidamide
  • Ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of pneumonia due to Pneumocystis carinii.
PharmacodynamicsPentamidine is an antiprotozoal agent. It is an aromatic diamidine, and is known to have activity against Pneumocystis carinii. The exact nature of its antiprotozoal action is unknown. in vitro studies with mammalian tissues and the protozoan Crithidia oncopelti indicate that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids and proteins. Little is known about the drug's pharmacokinetics. The medication is also useful in Leishmaniasis and in prophylaxis against sleeping sickness caused by Trypanosoma brucei gambiense. Hydration before treatment lessens the incidence and severity of side effects, which include liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, hypocalemia, leukopenia, thrombcytopenia, anemia, and allergic reaction. It is generally well-tolerated.
Mechanism of actionThe mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins.
Related Articles
AbsorptionAbsorbed poorly through the gastrointestinal tract and is usually administered parenterally.
Volume of distributionNot Available
Protein binding69%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life9.1-13.2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include pain, nausea, anorexia, hypotension, fever, rash, bad taste in mouth, confusion/hallucinations, dizziness, and diarrhea.
Affected organisms
  • Pneumocystis carinii
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9416
Blood Brain Barrier+0.9133
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5352
P-glycoprotein inhibitor INon-inhibitor0.8571
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.6653
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7339
CYP450 1A2 substrateNon-inhibitor0.5272
CYP450 2C9 inhibitorNon-inhibitor0.7439
CYP450 2D6 inhibitorNon-inhibitor0.7676
CYP450 2C19 inhibitorNon-inhibitor0.6581
CYP450 3A4 inhibitorNon-inhibitor0.8661
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5621
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8395
BiodegradationNot ready biodegradable0.9818
Rat acute toxicity2.2925 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7428
hERG inhibition (predictor II)Non-inhibitor0.7711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Armour pharmaceutical co
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Inhalantrespiratory (inhalation)300 mg/6mL
Powder for solutionintramuscular; inhalation; intravenous300 mg
Injection, powder, lyophilized, for solutionintramuscular; intravenous300 mg/3mL
Powder for solutionintramuscular; intravenous300 mg
Prices
Unit descriptionCostUnit
Nebupent 300 mg inhal powder122.84USD each
Pentam 300 vial94.8USD vial
Pentamidine 300 mg vial45.31USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point186.0 °C (decomposes)Not Available
water solubilityCompleteNot Available
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0236 mg/mLALOGPS
logP1.32ALOGPS
logP2.32ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)12.13ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area118.2 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity120.53 m3·mol-1ChemAxon
Polarizability38.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Nguewa PA, Fuertes MA, Cepeda V, Iborra S, Carrion J, Valladares B, Alonso C, Perez JM: Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers. 2005 Oct;2(10):1387-400. [PubMed:17191940 ]
External Links
ATC CodesP01CX01
AHFS Codes
  • 08:30.92
PDB Entries
FDA labelNot Available
MSDSDownload (50.6 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Pentamidine.
AbirateroneThe serum concentration of Pentamidine can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Pentamidine.
AcarboseAcarbose may increase the hypoglycemic activities of Pentamidine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pentamidine.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Pentamidine.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Pentamidine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Pentamidine.
AicarAicar may increase the hypoglycemic activities of Pentamidine.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pentamidine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pentamidine.
AlogliptinAlogliptin may increase the hypoglycemic activities of Pentamidine.
AmantadineAmantadine may increase the QTc-prolonging activities of Pentamidine.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Pentamidine.
AmiodaronePentamidine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Pentamidine can be decreased when combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Pentamidine.
AmlodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Amlodipine.
AmoxapineAmoxapine may increase the hypoglycemic activities of Pentamidine.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pentamidine.
AmrinoneThe risk or severity of adverse effects can be increased when Pentamidine is combined with Amrinone.
AnagrelidePentamidine may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Pentamidine.
AprepitantThe serum concentration of Pentamidine can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Pentamidine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pentamidine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Pentamidine.
ArmodafinilThe metabolism of Pentamidine can be decreased when combined with Armodafinil.
Arsenic trioxidePentamidine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherPentamidine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Pentamidine can be decreased when combined with Artemether.
AsenapinePentamidine may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Pentamidine.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Pentamidine.
AzelnidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Pentamidine is combined with Azimilide.
AzithromycinPentamidine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Pentamidine can be decreased when combined with Azithromycin.
BarnidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Barnidipine.
BedaquilinePentamidine may increase the QTc-prolonging activities of Bedaquiline.
BenidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Benidipine.
BenmoxinBenmoxin may increase the hypoglycemic activities of Pentamidine.
BepridilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Bepridil.
BetaxololThe metabolism of Pentamidine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Pentamidine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Pentamidine can be decreased when combined with Boceprevir.
BortezomibBortezomib may increase the QTc-prolonging activities of Pentamidine.
BosentanThe serum concentration of Pentamidine can be decreased when it is combined with Bosentan.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Pentamidine.
BuforminBuformin may increase the hypoglycemic activities of Pentamidine.
BupropionThe metabolism of Pentamidine can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Pentamidine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Pentamidine.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Pentamidine.
CaffeineThe metabolism of Pentamidine can be decreased when combined with Caffeine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentamidine.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Pentamidine.
CarbamazepineThe metabolism of Pentamidine can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Pentamidine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pentamidine.
CastanospermineCastanospermine may increase the hypoglycemic activities of Pentamidine.
CelecoxibThe metabolism of Pentamidine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Pentamidine can be increased when it is combined with Ceritinib.
CeritinibPentamidine may increase the QTc-prolonging activities of Ceritinib.
ChloramphenicolThe metabolism of Pentamidine can be decreased when combined with Chloramphenicol.
ChloroquinePentamidine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Pentamidine can be decreased when combined with Chloroquine.
ChlorpromazinePentamidine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Pentamidine can be decreased when combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pentamidine.
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Pentamidine.
CholecalciferolThe metabolism of Pentamidine can be decreased when combined with Cholecalciferol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pentamidine.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Pentamidine.
CilnidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Cilnidipine.
CimetidineThe metabolism of Pentamidine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Pentamidine can be decreased when combined with Cinacalcet.
CinnarizineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Cinnarizine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Pentamidine.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Pentamidine.
CitalopramCitalopram may increase the hypoglycemic activities of Pentamidine.
CitalopramPentamidine may increase the QTc-prolonging activities of Citalopram.
ClarithromycinPentamidine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Pentamidine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Pentamidine can be decreased when combined with Clobazam.
ClomipramineClomipramine may increase the hypoglycemic activities of Pentamidine.
ClopidogrelThe metabolism of Pentamidine can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Pentamidine can be decreased when combined with Clotrimazole.
ClozapinePentamidine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Pentamidine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Pentamidine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Pentamidine can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Pentamidine can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Pentamidine.
CrizotinibPentamidine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Pentamidine can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Pentamidine.
Cyproterone acetateThe serum concentration of Pentamidine can be decreased when it is combined with Cyproterone acetate.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Pentamidine.
DapoxetineDapoxetine may increase the hypoglycemic activities of Pentamidine.
DarifenacinThe metabolism of Pentamidine can be decreased when combined with Darifenacin.
DarodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Darodipine.
DarunavirThe serum concentration of Pentamidine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Pentamidine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Pentamidine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Pentamidine.
DelavirdineThe metabolism of Pentamidine can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Pentamidine.
DesipramineDesipramine may increase the QTc-prolonging activities of Pentamidine.
DexamethasoneThe serum concentration of Pentamidine can be decreased when it is combined with Dexamethasone.
DidanosineDidanosine can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiflunisalDiflunisal may increase the hypoglycemic activities of Pentamidine.
DihydroergotamineThe metabolism of Pentamidine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Pentamidine.
DiltiazemThe risk or severity of adverse effects can be increased when Pentamidine is combined with Diltiazem.
DiltiazemThe metabolism of Pentamidine can be decreased when combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Pentamidine.
DisopyramidePentamidine may increase the QTc-prolonging activities of Disopyramide.
DisopyramideDisopyramide may increase the hypoglycemic activities of Pentamidine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Pentamidine.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Pentamidine.
DolasetronPentamidine may increase the QTc-prolonging activities of Dolasetron.
DomperidonePentamidine may increase the QTc-prolonging activities of Domperidone.
DotarizineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Dotarizine.
DoxepinDoxepin may increase the QTc-prolonging activities of Pentamidine.
DoxycyclineThe metabolism of Pentamidine can be decreased when combined with Doxycycline.
DronedaronePentamidine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Pentamidine can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Pentamidine.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pentamidine.
DulaglutideDulaglutide may increase the hypoglycemic activities of Pentamidine.
DuloxetineThe metabolism of Pentamidine can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Pentamidine can be decreased when it is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Efonidipine.
EliglustatPentamidine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Pentamidine can be decreased when combined with Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pentamidine.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Pentamidine.
EnzalutamideThe serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide.
EperisoneThe risk or severity of adverse effects can be increased when Pentamidine is combined with Eperisone.
EribulinEribulin may increase the QTc-prolonging activities of Pentamidine.
ErythromycinPentamidine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Pentamidine can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Pentamidine.
EscitalopramPentamidine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Pentamidine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Pentamidine can be decreased when combined with Esomeprazole.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Pentamidine.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Pentamidine.
EtravirineThe serum concentration of Pentamidine can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Pentamidine.
ExenatideExenatide may increase the hypoglycemic activities of Pentamidine.
EzogabineEzogabine may increase the QTc-prolonging activities of Pentamidine.
FamotidineFamotidine may increase the QTc-prolonging activities of Pentamidine.
FelbamateFelbamate may increase the QTc-prolonging activities of Pentamidine.
FelodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Felodipine.
FelodipineThe metabolism of Pentamidine can be decreased when combined with Felodipine.
FendilineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Fendiline.
FenfluramineFenfluramine may increase the hypoglycemic activities of Pentamidine.
FingolimodFingolimod may increase the QTc-prolonging activities of Pentamidine.
FlecainidePentamidine may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Pentamidine.
FlunarizineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Flunarizine.
FluoxetineFluoxetine may increase the hypoglycemic activities of Pentamidine.
FluoxetinePentamidine may increase the QTc-prolonging activities of Fluoxetine.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Pentamidine.
FlupentixolPentamidine may increase the QTc-prolonging activities of Flupentixol.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Pentamidine.
FormoterolFormoterol may increase the QTc-prolonging activities of Pentamidine.
FosamprenavirThe metabolism of Pentamidine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pentamidine can be increased when it is combined with Fosaprepitant.
FoscarnetThe risk or severity of adverse effects can be increased when Pentamidine is combined with Foscarnet.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Pentamidine.
FosphenytoinThe serum concentration of Pentamidine can be decreased when it is combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Pentamidine.
Fusidic AcidThe serum concentration of Pentamidine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Pentamidine is combined with Gabapentin.
Gadobenic acidPentamidine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Pentamidine.
GemfibrozilThe metabolism of Pentamidine can be decreased when combined with Gemfibrozil.
GemifloxacinPentamidine may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pentamidine.
GlibornurideGlibornuride may increase the hypoglycemic activities of Pentamidine.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Pentamidine.
GliclazideGliclazide may increase the hypoglycemic activities of Pentamidine.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Pentamidine.
GlimepirideGlimepiride may increase the hypoglycemic activities of Pentamidine.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pentamidine.
GlipizideGlipizide may increase the hypoglycemic activities of Pentamidine.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pentamidine.
GliquidoneGliquidone may increase the hypoglycemic activities of Pentamidine.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pentamidine.
GlyburideGlyburide may increase the hypoglycemic activities of Pentamidine.
GoserelinGoserelin may increase the QTc-prolonging activities of Pentamidine.
GranisetronPentamidine may increase the QTc-prolonging activities of Granisetron.
HaloperidolPentamidine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Pentamidine can be decreased when combined with Haloperidol.
HistrelinHistrelin may increase the QTc-prolonging activities of Pentamidine.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Pentamidine.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Pentamidine.
IbandronateIbandronate may increase the QTc-prolonging activities of Pentamidine.
IbutilidePentamidine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Pentamidine can be increased when it is combined with Idelalisib.
IloperidonePentamidine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Pentamidine can be decreased when combined with Imatinib.
ImipramineImipramine may increase the QTc-prolonging activities of Pentamidine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pentamidine.
IndalpineIndalpine may increase the hypoglycemic activities of Pentamidine.
IndapamideIndapamide may increase the QTc-prolonging activities of Pentamidine.
IndinavirThe metabolism of Pentamidine can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Pentamidine.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Pentamidine.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Pentamidine.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Pentamidine.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Pentamidine.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Pentamidine.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Pentamidine.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Pentamidine.
Insulin HumanInsulin Human may increase the hypoglycemic activities of Pentamidine.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Pentamidine.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Pentamidine.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pentamidine.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Pentamidine.
IproclozideIproclozide may increase the hypoglycemic activities of Pentamidine.
IproniazidIproniazid may increase the hypoglycemic activities of Pentamidine.
IrbesartanThe metabolism of Pentamidine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Pentamidine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Pentamidine.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pentamidine.
IsoniazidThe metabolism of Pentamidine can be decreased when combined with Isoniazid.
IsradipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Isradipine.
IsradipineIsradipine may increase the QTc-prolonging activities of Pentamidine.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Pentamidine.
IvabradineIvabradine may increase the QTc-prolonging activities of Pentamidine.
IvacaftorThe serum concentration of Pentamidine can be increased when it is combined with Ivacaftor.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Pentamidine.
LacidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lacidipine.
LamotrigineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lamotrigine.
LanreotidePentamidine may increase the hypoglycemic activities of Lanreotide.
LapatinibLapatinib may increase the QTc-prolonging activities of Pentamidine.
LenvatinibPentamidine may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lercanidipine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pentamidine.
LevofloxacinPentamidine may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Pentamidine.
LidocaineThe metabolism of Pentamidine can be decreased when combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Pentamidine.
LinagliptinLinagliptin may increase the hypoglycemic activities of Pentamidine.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Pentamidine.
LiraglutideLiraglutide may increase the hypoglycemic activities of Pentamidine.
LithiumLithium may increase the QTc-prolonging activities of Pentamidine.
LopinavirPentamidine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Pentamidine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Pentamidine can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Losartan can be decreased when combined with Pentamidine.
LovastatinThe metabolism of Pentamidine can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Pentamidine.
LuliconazoleThe serum concentration of Pentamidine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pentamidine can be decreased when it is combined with Lumacaftor.
LumefantrinePentamidine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Pentamidine can be decreased when combined with Lumefantrine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pentamidine is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Manidipine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Pentamidine.
MebanazineMebanazine may increase the hypoglycemic activities of Pentamidine.
MecaserminPentamidine may increase the hypoglycemic activities of Mecasermin.
MefloquineMefloquine may increase the QTc-prolonging activities of Pentamidine.
MequitazinePentamidine may increase the arrhythmogenic activities of Mequitazine.
MesalazineMesalazine may increase the hypoglycemic activities of Pentamidine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.
MetforminMetformin may increase the hypoglycemic activities of Pentamidine.
MethadonePentamidine may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Pentamidine can be decreased when combined with Methadone.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Pentamidine.
Methylene blueMethylene blue may increase the hypoglycemic activities of Pentamidine.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Pentamidine.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Pentamidine.
MetoprololThe metabolism of Pentamidine can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pentamidine.
MexiletineThe metabolism of Pentamidine can be decreased when combined with Mexiletine.
MibefradilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Mibefradil.
MifepristoneMifepristone may increase the QTc-prolonging activities of Pentamidine.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pentamidine.
MiglitolMiglitol may increase the hypoglycemic activities of Pentamidine.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Pentamidine.
MiglustatMiglustat may increase the hypoglycemic activities of Pentamidine.
MilnacipranMilnacipran may increase the hypoglycemic activities of Pentamidine.
MinaprineMinaprine may increase the hypoglycemic activities of Pentamidine.
MirabegronMirabegron may increase the QTc-prolonging activities of Pentamidine.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Pentamidine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pentamidine.
MitiglinideMitiglinide may increase the hypoglycemic activities of Pentamidine.
MitotaneThe serum concentration of Pentamidine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypoglycemic activities of Pentamidine.
ModafinilThe serum concentration of Pentamidine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Pentamidine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pentamidine.
NafcillinThe serum concentration of Pentamidine can be decreased when it is combined with Nafcillin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Pentamidine.
NateglinideNateglinide may increase the hypoglycemic activities of Pentamidine.
NefazodoneThe metabolism of Pentamidine can be decreased when combined with Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Pentamidine.
NetupitantThe serum concentration of Pentamidine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pentamidine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypoglycemic activities of Pentamidine.
NicardipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nicardipine.
NicardipineNicardipine may increase the QTc-prolonging activities of Pentamidine.
NifedipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nifedipine.
NiguldipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Niguldipine.
NilotinibPentamidine may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Pentamidine can be decreased when combined with Nilotinib.
NiludipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Niludipine.
NilvadipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimodipine.
NisoldipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nisoldipine.
NitrendipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pentamidine.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pentamidine.
OctamoxinOctamoxin may increase the hypoglycemic activities of Pentamidine.
OctreotideOctreotide may increase the QTc-prolonging activities of Pentamidine.
OctreotidePentamidine may increase the hypoglycemic activities of Octreotide.
OfloxacinPentamidine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the hypoglycemic activities of Pentamidine.
OlaparibThe metabolism of Pentamidine can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pentamidine.
OmeprazoleThe metabolism of Pentamidine can be decreased when combined with Omeprazole.
OndansetronPentamidine may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Pentamidine can be increased when it is combined with Osimertinib.
OxandroloneOxandrolone may increase the hypoglycemic activities of Pentamidine.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Pentamidine.
OxytocinOxytocin may increase the QTc-prolonging activities of Pentamidine.
PalbociclibThe serum concentration of Pentamidine can be increased when it is combined with Palbociclib.
PaliperidonePentamidine may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPentamidine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Pentamidine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pentamidine can be decreased when combined with Pantoprazole.
PargylinePargyline may increase the hypoglycemic activities of Pentamidine.
ParoxetineParoxetine may increase the hypoglycemic activities of Pentamidine.
PasireotidePasireotide may increase the QTc-prolonging activities of Pentamidine.
PasireotidePentamidine may increase the hypoglycemic activities of Pasireotide.
PazopanibPentamidine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantPegvisomant may increase the hypoglycemic activities of Pentamidine.
PentobarbitalThe metabolism of Pentamidine can be increased when combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Pentamidine.
PerhexilineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Perhexiline.
PhenelzinePhenelzine may increase the hypoglycemic activities of Pentamidine.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Pentamidine.
PhenforminPhenformin may increase the hypoglycemic activities of Pentamidine.
PheniprazinePheniprazine may increase the hypoglycemic activities of Pentamidine.
PhenobarbitalThe metabolism of Pentamidine can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Pentamidine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pentamidine.
PhenytoinThe metabolism of Pentamidine can be increased when combined with Phenytoin.
PimozidePentamidine may increase the arrhythmogenic activities of Pimozide.
PinaveriumThe risk or severity of adverse effects can be increased when Pentamidine is combined with Pinaverium.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pentamidine.
PioglitazonePioglitazone may increase the hypoglycemic activities of Pentamidine.
PirlindolePirlindole may increase the hypoglycemic activities of Pentamidine.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Pentamidine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Pentamidine.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Pentamidine.
PramlintidePramlintide may increase the hypoglycemic activities of Pentamidine.
PregabalinThe risk or severity of adverse effects can be increased when Pentamidine is combined with Pregabalin.
PrenylamineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Prenylamine.
PrimaquinePentamidine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Pentamidine can be increased when combined with Primidone.
ProcainamidePentamidine may increase the QTc-prolonging activities of Procainamide.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Pentamidine.
PromazinePentamidine may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Pentamidine can be decreased when combined with Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Pentamidine.
PropafenonePentamidine may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Pentamidine.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Pentamidine.
QuetiapinePentamidine may increase the QTc-prolonging activities of Quetiapine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Pentamidine.
QuininePentamidine may increase the QTc-prolonging activities of Quinine.
QuinineQuinine may increase the hypoglycemic activities of Pentamidine.
RabeprazoleThe metabolism of Pentamidine can be decreased when combined with Rabeprazole.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Pentamidine.
RanolazineRanolazine may increase the QTc-prolonging activities of Pentamidine.
RasagilineRasagiline may increase the hypoglycemic activities of Pentamidine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Pentamidine.
RepaglinideRepaglinide may increase the hypoglycemic activities of Pentamidine.
RifabutinThe metabolism of Pentamidine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Pentamidine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Pentamidine can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Pentamidine.
RisedronateThe risk or severity of adverse effects can be increased when Pentamidine is combined with Risedronate.
RisperidoneRisperidone may increase the QTc-prolonging activities of Pentamidine.
RitonavirRitonavir may increase the QTc-prolonging activities of Pentamidine.
RolapitantThe metabolism of Pentamidine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Pentamidine can be decreased when combined with Ropinirole.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pentamidine.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Pentamidine.
SafrazineSafrazine may increase the hypoglycemic activities of Pentamidine.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pentamidine.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Pentamidine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pentamidine.
SaquinavirPentamidine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pentamidine.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Pentamidine.
SecobarbitalThe metabolism of Pentamidine can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypoglycemic activities of Pentamidine.
SertralineSertraline may increase the hypoglycemic activities of Pentamidine.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pentamidine.
SildenafilThe metabolism of Pentamidine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Pentamidine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pentamidine can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pentamidine.
SitagliptinSitagliptin may increase the hypoglycemic activities of Pentamidine.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Pentamidine.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Pentamidine.
SorafenibSorafenib may increase the QTc-prolonging activities of Pentamidine.
SotalolPentamidine may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Pentamidine can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hypoglycemic activities of Pentamidine.
StiripentolThe serum concentration of Pentamidine can be increased when it is combined with Stiripentol.
SucralfateSucralfate can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Pentamidine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Pentamidine.
SulfamethoxazolePentamidine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Pentamidine.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pentamidine.
SulodexideSulodexide may increase the hypoglycemic activities of Pentamidine.
SunitinibSunitinib may increase the QTc-prolonging activities of Pentamidine.
SunitinibPentamidine may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Pentamidine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Pentamidine.
TelaprevirThe metabolism of Pentamidine can be decreased when combined with Telaprevir.
TelavancinPentamidine may increase the QTc-prolonging activities of Telavancin.
TelithromycinPentamidine may increase the QTc-prolonging activities of Telithromycin.
TenofovirThe metabolism of Pentamidine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Pentamidine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pentamidine.
TeriflunomideThe serum concentration of Pentamidine can be decreased when it is combined with Teriflunomide.
TestosteroneTestosterone may increase the hypoglycemic activities of Pentamidine.
TetrabenazinePentamidine may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe metabolism of Pentamidine can be decreased when combined with Theophylline.
ThioridazinePentamidine may increase the QTc-prolonging activities of Thioridazine.
ThioridazineThe metabolism of Pentamidine can be decreased when combined with Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pentamidine.
TiclopidineThe metabolism of Pentamidine can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Pentamidine can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Pentamidine.
TocilizumabThe serum concentration of Pentamidine can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pentamidine.
TolazamideTolazamide may increase the hypoglycemic activities of Pentamidine.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pentamidine.
TolbutamideTolbutamide may increase the hypoglycemic activities of Pentamidine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tolfenamic Acid.
ToloxatoneToloxatone may increase the hypoglycemic activities of Pentamidine.
TolterodineTolterodine may increase the QTc-prolonging activities of Pentamidine.
TopiramateThe metabolism of Pentamidine can be decreased when combined with Topiramate.
ToremifenePentamidine may increase the QTc-prolonging activities of Toremifene.
TranilastThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pentamidine.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Pentamidine.
TrazodoneTrazodone may increase the hypoglycemic activities of Pentamidine.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pentamidine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Pentamidine.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Pentamidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pentamidine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Pentamidine.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Pentamidine.
VandetanibPentamidine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Pentamidine.
VemurafenibThe serum concentration of Pentamidine can be increased when it is combined with Vemurafenib.
VemurafenibPentamidine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Pentamidine.
VerapamilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Verapamil.
VerapamilThe metabolism of Pentamidine can be decreased when combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Pentamidine.
VilazodoneVilazodone may increase the hypoglycemic activities of Pentamidine.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pentamidine.
VildagliptinVildagliptin may increase the hypoglycemic activities of Pentamidine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Pentamidine.
VogliboseVoglibose may increase the hypoglycemic activities of Pentamidine.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Pentamidine.
VorinostatVorinostat may increase the QTc-prolonging activities of Pentamidine.
VortioxetineVortioxetine may increase the hypoglycemic activities of Pentamidine.
XylometazolineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Xylometazoline.
ZiconotideThe risk or severity of adverse effects can be increased when Pentamidine is combined with Ziconotide.
ZimelidineZimelidine may increase the hypoglycemic activities of Pentamidine.
ZiprasidonePentamidine may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Pentamidine can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Pentamidine.
ZuclopenthixolPentamidine may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
unknown
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Shankar SM, Nania JJ: Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs. 2007;9(5):301-9. [PubMed:17927302 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Trna methyltransferase activity
Specific Function:
Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp).
Gene Name:
TRDMT1
Uniprot ID:
O14717
Molecular Weight:
44596.17 Da
References
  1. Sun T, Zhang Y: Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation. Nucleic Acids Res. 2008 Mar;36(5):1654-64. doi: 10.1093/nar/gkm1180. Epub 2008 Feb 7. [PubMed:18263620 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Afrin LB, Afrin JB: Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5. doi: 10.1111/j.1399-0012.2011.01399.x. Epub 2011 Feb 7. [PubMed:21299635 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23